MCID: HYP263
MIFTS: 37

Hypersomnia

Categories: Mental diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hypersomnia

MalaCards integrated aliases for Hypersomnia:

Name: Hypersomnia 52 16 71 75
Hypersomnolence Due to Substances Including Medications 33
Hypersomnia Due to Substances Including Medications 33

Classifications:



External Ids:

UMLS 71 C0917799

Summaries for Hypersomnia

NINDS: 52 Hypersomnia is characterized by recurrent episodes of excessive daytime sleepiness or prolonged nighttime sleep. Different from feeling tired due to lack of or interrupted sleep at night, persons with hypersomnia are compelled to nap repeatedly during the day, often at inappropriate times such as at work, during a meal, or in conversation. These daytime naps usually provide no relief from symptoms. Patients often have difficulty waking from a long sleep, and may feel disoriented. Other symptoms may include anxiety, increased irritation, decreased energy, restlessness, slow thinking, slow speech, loss of appetite, hallucinations, and memory difficulty. Some patients lose the ability to function in family, social, occupational, or other settings. Hypersomnia may be caused by another sleep disorder (such as narcolepsy or sleep apnea), dysfunction of the autonomic nervous system, or drug or alcohol abuse. In some cases it results from a physical problem, such as a tumor, head trauma, or injury to the central nervous system. Certain medications, or medicine withdrawal, may also cause hypersomnia. Medical conditions including multiple sclerosis, depression, encephalitis, epilepsy, or obesity may contribute to the disorder. Some people appear to have a genetic predisposition to hypersomnia; in others, there is no known cause. Typically, hypersomnia is first recognized in adolescence or young adulthood.

MalaCards based summary: Hypersomnia, also known as hypersomnolence due to substances including medications, is related to kleine-levin hibernation syndrome and recurrent hypersomnia, and has symptoms including excessive daytime somnolence, snoring and sleep disturbances. An important gene associated with Hypersomnia is HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1). The drugs Sodium oxybate and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and hypothalamus, and related phenotypes are Decreased viability and nervous system

Wikipedia: 75 Hypersomnia is a neurological disorder of excessive time spent sleeping or excessive sleepiness. It can... more...

Related Diseases for Hypersomnia

Diseases in the Hypersomnia family:

Recurrent Hypersomnia

Diseases related to Hypersomnia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 235)
# Related Disease Score Top Affiliating Genes
1 kleine-levin hibernation syndrome 32.0 HLA-DQB1 HCRT
2 recurrent hypersomnia 31.9 HLA-DQB1 HCRT
3 idiopathic hypersomnia 31.4 PTGDS OPN4 HLA-DQB1 HCRT
4 sleep disorder 30.9 OPN4 HLA-DQB1 HCRT
5 narcolepsy 1 30.8 HLA-DQB1 HCRT
6 narcolepsy 30.7 PTGDS HLA-DQB1 HCRT
7 narcolepsy 2 30.5 HLA-DQB1 HCRT
8 neuromyelitis optica 29.9 HLA-DQB1 HCRT
9 periodic limb movement disorder 29.4 HLA-DQB1 HCRT
10 delayed sleep phase disorder 29.3 OPN4 HCRT
11 migraine with or without aura 1 29.2 OPN4 HCRT
12 guillain-barre syndrome 29.2 HLA-DQB1 HCRT
13 major depressive disorder 11.0
14 dystonia, dopa-responsive, due to sepiapterin reductase deficiency 11.0
15 myotonic dystrophy 2 10.9
16 atypical depressive disorder 10.9
17 cranioectodermal dysplasia 10.5
18 sleep apnea 10.5
19 apnea, obstructive sleep 10.4
20 bipolar disorder 10.4
21 mood disorder 10.3
22 myotonic dystrophy 1 10.2
23 obesity-hypoventilation syndrome 10.2
24 bulimia nervosa 10.2
25 encephalitis 10.1
26 encephalopathy 10.1
27 restless legs syndrome 10.1
28 dysthymic disorder 10.1
29 movement disease 10.1
30 traumatic brain injury 10.1
31 prader-willi syndrome 10.0
32 ocular motor apraxia 10.0
33 kearns-sayre syndrome 10.0
34 congenital central hypoventilation syndrome 10.0
35 brain cancer 10.0
36 acute disseminated encephalomyelitis 10.0
37 rem sleep behavior disorder 10.0
38 multiple sclerosis 10.0
39 attention deficit-hyperactivity disorder 10.0
40 anxiety 10.0
41 autonomic nervous system disease 10.0
42 endogenous depression 10.0
43 pfeiffer syndrome 9.9
44 tobacco addiction 9.9
45 major affective disorder 2 9.9
46 stroke, ischemic 9.9
47 restless legs syndrome 6 9.9
48 major affective disorder 7 9.9
49 limbic encephalitis 9.9
50 central diabetes insipidus 9.9

Graphical network of the top 20 diseases related to Hypersomnia:



Diseases related to Hypersomnia

Symptoms & Phenotypes for Hypersomnia

UMLS symptoms related to Hypersomnia:


excessive daytime somnolence; snoring; sleep disturbances; sleeplessness; insomnia with sleep apnea, unspecified; hypersomnia with sleep apnea, unspecified; disruption of 24 hour sleep wake cycle, unspecified; [d]sleep disturbances (& [hypersomnia] or [insomnia])

GenomeRNAi Phenotypes related to Hypersomnia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00249-S 9.1 OPN4
2 Decreased viability GR00381-A-1 9.1 HLA-DQB1 OPN4
3 Decreased viability GR00381-A-3 9.1 HLA-DQB1 OPN4
4 Decreased viability GR00402-S-2 9.1 HLA-DQB1

MGI Mouse Phenotypes related to Hypersomnia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 8.92 HCRT HLA-DQB1 OPN4 PTGDS

Drugs & Therapeutics for Hypersomnia

Drugs for Hypersomnia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 34)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium oxybate Approved Phase 2, Phase 3 502-85-2 23663870
2
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2 23431961
3
Histamine Approved, Investigational Phase 3 51-45-6 774
4
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
5 Anesthetics, Intravenous Phase 2, Phase 3
6 Anesthetics, General Phase 2, Phase 3
7 Anesthetics Phase 2, Phase 3
8 Pharmaceutical Solutions Phase 2, Phase 3
9 Citrate Phase 2, Phase 3
10
Histamine phosphate Phase 3 51-74-1 134614
11
Flumazenil Approved Phase 1, Phase 2 78755-81-4 3373
12
Clarithromycin Approved Phase 2 81103-11-9 84029
13
Dextroamphetamine Approved, Illicit, Investigational Phase 2 51-64-9, 300-62-9 5826 3007
14
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
15
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
16
Pentetrazol Experimental, Withdrawn Phase 2 54-95-5
17 Convulsants Phase 2
18 Antidotes Phase 1, Phase 2
19 GABA Modulators Phase 1, Phase 2
20 Protective Agents Phase 1, Phase 2
21 Neurotransmitter Agents Phase 2
22 Anti-Bacterial Agents Phase 2
23 Anti-Infective Agents Phase 2
24 Cytochrome P-450 Enzyme Inhibitors Phase 2
25 Cytochrome P-450 CYP3A Inhibitors Phase 2
26 Central Nervous System Stimulants Phase 2
27 Antibiotics, Antitubercular Phase 2
28 Adrenergic Agents Phase 2
29 Dopamine Uptake Inhibitors Phase 2
30 Adderall Phase 2
31 Dopamine Agents Phase 2
32 Sympathomimetics Phase 2
33
Caffeine Approved 58-08-2 2519
34
Melatonin Approved, Nutraceutical, Vet_approved 73-31-4 896

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension Completed NCT03533114 Phase 3 JZP-258;Placebo Oral Solution
2 The Role of Palliative Care Interventions to Reduce Circadian Rhythm Disorders in Persons With Dementia: The Healthy Patterns Study Completed NCT03682185 Phase 3
3 A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia Recruiting NCT05156047 Phase 3 Pitolisant Oral Tablet;Placebo oral tablet
4 A Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Tolerance of Sodium Oxybate in Patients Affected With Idiopathic Hypersomnia Recruiting NCT03597555 Phase 2, Phase 3 Sodium Oxybate Oral Solution 500 MG/ML;Placebos
5 An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 Enrolling by invitation NCT05458128 Phase 3 pitolisant
6 A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia Unknown status NCT03542851 Phase 2 Pentetrazol (PTZ);Placebo oral capsule
7 A Ten Subject, Double-Blind, Placebo-Controlled Trial of Single Day Dosing of Sublingual Flumazenil in Individuals With Primary Hypersomnia or Excessively Long Total Sleep Time and Excess Endogenous Potentiation of GABA-A Receptors Completed NCT01183312 Phase 1, Phase 2 Flumazenil
8 Clarithromycin for the Treatment of Hypersomnia Completed NCT01146600 Phase 2 Clarithromycin followed by placebo;Placebo then Clarithromycin
9 A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 Completed NCT02512588 Phase 2 BTD-001;Placebo
10 Antibiotic-mediated Improvements in Vigilance: Mechanisms of Action of Clarithromycin in Hypersomnia Syndromes Recruiting NCT04026958 Phase 2 Clarithromycin;Placebo
11 Informing Treatment Decisions in the Central Disorders of Hypersomnolence: A Pragmatic Clinical Trial of Modafinil Versus Amphetamines Recruiting NCT03772314 Phase 2 Modafinil;Amphetamine-Dextroamphetamine
12 A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia Completed NCT04091438 Phase 1 TAK-925;TAK-925 Placebo
13 Hypersomnia in Major Depressive Disorder Unknown status NCT04006834
14 Prevalence and Characteristics of Sleep Disturbances Among Psychiatric Inpatients Unknown status NCT04201392
15 Effects of Telemedicine and Humidification for Continous Positive Airway Pressure (CPAP) in OSAS. Unknown status NCT04300166
16 Importance of Sleep Deprivation in Differential Diagnosis of Primary Hypersomnia in Reference Centers Rare Hypersomnia Completed NCT03459300
17 Evaluation of Excessive Diurnal Sleepiness by the Expression and Activity of Salivary Amylase in Children With Hypersomnia. Completed NCT01926405
18 Psychosocial Adjunctive Treatment for Hypersomnia (PATH): A Pilot Trial Completed NCT03904238
19 Assessing the Effect of the MYODM Food Supplement on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 Completed NCT04634682
20 Cardiovascular Variability and Heart Rate Arousal Response in Idiopathic Hypersomnia Completed NCT02913651
21 Neurophysiologic Correlates of Hypersomnia: a High Density EEG Investigation Completed NCT01719315
22 The Role of the Circadian System in Neurological Sleep-wake Disorders: Assessment of Circadian and Homeostatic Sleep-wake Regulation and Vigilance With a Poly-nap Protocol Completed NCT03356938
23 Anesthetic Management of Patients With Chronic Sleep Disorders Completed NCT04827329
24 Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study (SMART DOCS) Completed NCT02037438
25 Population-bases Study to Asses Prevalence of Sleep Disorders and Their Association With Cardiovascular Risk Factors and Diseases Completed NCT01877616
26 The Feasibility of a Tailored Music Intervention to Reduce Symptoms of Sleep Disruption in Older Adults With Dementia Completed NCT04157244
27 Training Protocol for Various Sleep Disorders in Patients With Neurological Disorders Completed NCT00001664
28 Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies, Impact of Modafinil Treatment. Completed NCT00916253 Modafinil;Placebo
29 The Effects of Mindfulness on Disrupted Sleep in Bipolar Disorder Completed NCT01764035
30 Coordination of Rare Diseases at Sanford Recruiting NCT01793168
31 Analysis of New Salivary Biomarkers to Evaluate Excessive Diurnal Sleepiness in Children With Hypersomnia Recruiting NCT05183464
32 Swiss Primary Hypersomnolence and Narcolepsy Cohort Study Recruiting NCT04330963
33 Study on Disease Course and Quality of Life in Patients With Sleep Disorders (Mainz Sleep Registry) Recruiting NCT05321355
34 A Multi-Signal Based Monitoring System for CNS Hypersomnias : A 10-year Longitudinal Study Recruiting NCT05443373
35 Validating the Use of a Novel Subjectively Reported Sleep Vital Sign for the Identification and Management of Sleep Disorders Active, not recruiting NCT03018912
36 Idiopathic Hypersomnia - a Retrospective Characterization Study Enrolling by invitation NCT05150977
37 Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments Enrolling by invitation NCT05371483
38 Feasibility Study of Utilizing At-Home Electroencephalography Monitoring for Diagnosing and Treatment Monitoring of Hypersomnia Not yet recruiting NCT05627388
39 Multiple Reaction Monitoring (MRM) Versus I 125 Radioimmunoassay (RIA) for the Quantification of Orexin-A/Hypocretin-1 Levels in Cerebrospinal Fluid: a Prospective Diagnostic Validation Study in Patients With Hypersomnolence Not yet recruiting NCT05615584
40 Randomized Control Trial to Compare Patient Outcomes Following Unattended Polysomnography Versus In-lab Polysomnography for Sleep Apnea and Comorbid Sleep Disorders Not yet recruiting NCT05230394
41 Disrupted Sleep in the Elderly: Light Exposure Studies Suspended NCT00427323
42 'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy' Suspended NCT04419792
43 Transcranial Direct Current Stimulation Therapy for Central Hypersomnia Without Cataplexy Terminated NCT03198156
44 Effect of a Structured Physical Activity Program on Sleep Quality and Sleepiness in Parkinson's Disease Terminated NCT01544465
45 Open-label Clinical Trial to Evaluate the Efficacy of Sodium Oxybate (Xyrem®) in the Treatment of Two Under-recognized Clinical Conditions: Post-traumatic Narcolepsy and Post-traumatic Hypersomnia Withdrawn NCT03626727 Early Phase 1 Sodium Oxybate Oral Solution [Xyrem]

Search NIH Clinical Center for Hypersomnia

Genetic Tests for Hypersomnia

Anatomical Context for Hypersomnia

Organs/tissues related to Hypersomnia:

MalaCards : Brain, Heart, Hypothalamus, Thalamus, Prefrontal Cortex, Eye, Globus Pallidus

Publications for Hypersomnia

Articles related to Hypersomnia:

(show top 50) (show all 2061)
# Title Authors PMID Year
1
Prevalence of obstructive sleep apnea as assessed by polysomnography in psychiatric patients with sleep-related problems. 62
35029795 2022
2
Associations of somatic depressive symptoms with body mass index, systemic inflammation, and insulin resistance in primary care patients with depression. 62
36074315 2022
3
Differentiation of central disorders of hypersomnolence with manual and artificial-intelligence-derived polysomnographic measures. 62
36455881 2022
4
Clinical considerations for the diagnosis of idiopathic hypersomnia. 62
36401976 2022
5
Association between blood pressure and parameters related to sleep disorders in Tabari cohort population. 62
36376986 2022
6
Symmetrical isolated globus pallidus infarction due to bilateral carotid artery dissection. 62
35915270 2022
7
Central hypersomnia and chronic insomnia: expanding the spectrum of sleep disorders in long COVID syndrome - a prospective cohort study. 62
36352367 2022
8
Sleep outcomes in pediatric mild traumatic brain injury: a systematic review and meta-analysis of prevalence and contributing factors. 62
36413091 2022
9
Central Disorders of Hypersomnolence: Association with Fatigue, Depression and Sleep Inertia Prevailing in Women. 62
36358417 2022
10
Sociodemographic, lifestyle and clinical characteristics of energy-related depression symptoms: A pooled analysis of 13,965 depressed cases in 8 Dutch cohorts. 62
36372132 2022
11
Sleep and circadian rhythm profiles in seasonal depression. 62
36244199 2022
12
Changes in Sleep Pattern During the COVID-19 Lockdown in Patients With Narcolepsy, Idiopathic Hypersomnia, and Restless Legs Syndrome. 62
35918167 2022
13
Sleep and Phelan-McDermid Syndrome: Lessons from the International Registry and the scientific literature. 62
35996993 2022
14
Low carnitine palmitoyltransferase 1 activity is a risk factor for narcolepsy type 1 and other hypersomnia. 62
35810398 2022
15
Repeated measures of hypocretin-1 in Danish and Italian patients with narcolepsy and in controls. 62
36427467 2022
16
Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model. 62
36108771 2022
17
Socioeconomic status and sleep health: a narrative synthesis of three decades of empirical research. 62
36239056 2022
18
Is it time for a gold standard in the diagnosis of hypersomnia? 62
35924659 2022
19
Excessive daytime sleepiness: an emerging marker of cardiovascular risk. 62
35102000 2022
20
Reader Response: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study. 62
36253127 2022
21
Editors' Note: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study. 62
36253129 2022
22
Author Response: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study. 62
36253130 2022
23
Central disorders of hypersomnolence: diagnostic discrepancies between military and civilian sleep centers. 62
35855527 2022
24
French Sleepiness Scale for Adolescents-8 items: A discriminant and diagnostic validation. 62
36253180 2022
25
Sleep quality and risk of recurrent aphthous ulcers: A Spanish cohort study. 62
34242451 2022
26
Comparison of the efficacy of ultrasound-guided erector spinae plane block and thoracic paravertebral block combined with intercostal nerve block for pain management in video-assisted thoracoscopic surgery: a prospective, randomized, controlled clinical trial. 62
36088297 2022
27
Orexin Receptor Agonists as Possible Treatment for Narcolepsy and Idiopathic Hypersomnia. 62
36105332 2022
28
Precision Medicine for Idiopathic Hypersomnia. 62
36150801 2022
29
Diabetes, sleep disorders and risk of depression - A Danish register-based cohort study. 62
35932548 2022
30
Pharmacologic Management of Excessive Daytime Sleepiness. 62
36150809 2022
31
Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort. 62
35750949 2022
32
Altered Behavioral Responses Show GABA Sensitivity in Muscleblind-Like 2-Deficient Mice: Implications for CNS Symptoms in Myotonic Dystrophy. 62
36150891 2022
33
Kleine-Levin syndrome: report of a case with marked dysautonomic features. 62
35393940 2022
34
Proteomic biomarkers of Kleine-Levin syndrome. 62
35859339 2022
35
Understanding and approaching excessive daytime sleepiness. 62
36115367 2022
36
Leigh-Like Syndrome With a Novel, Complex Phenotype Due to m.10191T>C in Mt-ND3. 62
36249637 2022
37
Sleepiness in obstructive sleep apnea using hypopneas defined by a 3% oxygen desaturation or arousal but not by 4% or greater oxygen desaturation. 62
34564819 2022
38
Sleep disorders in children with asthma. 62
33647191 2022
39
Parental burnout and sleep problems in Iranian mothers of primary school-aged children: Exploring the mediation effect of emotional schemas. 62
35849708 2022
40
[Cognitive disorders and sleep disturbances in long COVID]. 62
35576015 2022
41
Usefulness of the maintenance of wakefulness test in central disorders of hypersomnolence: a scoping review. 62
35429267 2022
42
[Diagnostic strategy for hypersomnolence disorders]. 62
35184867 2022
43
Recognizing New-Onset Sleep Disorders in Autoimmune Encephalitis Often Prompt Earlier Diagnosis. 62
35239557 2022
44
Prevalence, Incidence and Health Impacts of Sleep Disorders on Coronary Artery Disease Risk Factors: Results of a Community-Based Cohort Study (KERCADRS). 62
36474691 2022
45
Mental Health Conditions According to Stress and Sleep Disorders. 62
35805615 2022
46
Diagnosis and management of sleep disorders in Prader-Willi syndrome. 62
35172921 2022
47
Autoimmune conditions following mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccination: A descriptive cohort study among 1.1 million vaccinated people in Hong Kong. 62
35461018 2022
48
Comparative polysomnography parameters between narcolepsy type 1/type 2 and idiopathic hypersomnia: A systematic review and meta-analysis. 62
35278894 2022
49
IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis. 62
35731078 2022
50
Dynamic networks of psychological symptoms, impairment, substance use, and social support: The evolution of psychopathology among emerging adults. 62
35694845 2022

Variations for Hypersomnia

Expression for Hypersomnia

Search GEO for disease gene expression data for Hypersomnia.

Pathways for Hypersomnia

GO Terms for Hypersomnia

Cellular components related to Hypersomnia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 rough endoplasmic reticulum GO:0005791 8.92 PTGDS HCRT

Sources for Hypersomnia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....